Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 621 results found since Jan 2013.
Transcatheter Left Atrial Appendage Closure
Methodist Debakey Cardiovasc J. 2023 May 16;19(3):67-77. doi: 10.14797/mdcvj.1215. eCollection 2023.ABSTRACTAtrial fibrillation is the most common arrhythmia worldwide, placing a large population at risk for potentially disabling ischemic strokes, yet an estimated 50% of eligible patients cannot tolerate or are contraindicated to receive oral anticoagulation. Within the last 15 years, transcatheter options for left atrial appendage closure (LAAC) have provided a valuable alternative to chronic oral anticoagulation for reducing risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. With newer...
Source: Methodist DeBakey Cardiovascular Journal - May 22, 2023 Category: Cardiology Authors: Gordon X Wong Gagan D Singh Source Type: research
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian's first U.S. FDA Fast Track Designation for the prevention of stroke in patients after a non-cardioembolic ischemic stroke, which was granted in 2022.
Source: World Pharma News - May 16, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
FDA Approves New Menopause Drug for Hot Flashes
WASHINGTON — U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause.
The Food and Drug Administration approved the once-a-day pill from Astellas Pharma to treat moderate-to-severe symptoms, which can include sweating, flushing and chills.
Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective treatment option for women,” in a statement.
More than 80% of women experience hot flashes during menopause,...
Source: TIME: Health - May 15, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Mayo Clinic Minute: How vagus nerve stimulation can help some patients improve their recovery after stroke
A vagus nerve stimulation device, approved by the Food and Drug Administration, is being used in rehabilitation to help patients recovering from an ischemic stroke. If a patient is having trouble using their hand or arm after a stroke, this stimulation device helps create new pathways in the brain as the person performs exercises. This can help the person regain function faster than rehabilitation alone. Dr. Jonathon Parker, a Mayo Clinic neurosurgeon, discusses how the…
Source: News from Mayo Clinic - May 2, 2023 Category: Databases & Libraries Source Type: news
FDA clears RapidAI's CT imaging stroke assessment software
The U.S. Food and Drug Administration (FDA) has cleared artificial intelligenc...Read more on AuntMinnie.comRelated Reading:
RapidAI receives FDA clearance for Rapid RV/LV
RapidAI gets FDA nod for ICH algorithm
RapidAI earns FDA clearance for PE triage software
RapidAI names Phadnis as new technology executive
RapidAI taps Karim Karti as its new CEO
Source: AuntMinnie.com Headlines - April 18, 2023 Category: Radiology Source Type: news
Clinical trial participant ’s autopsy and brain exam stoke Alzheimer’s drug fears
A full autopsy and detailed examination of the brain of a 79-year-old Florida woman who died after receiving lecanemab, an experimental Alzheimer’s therapy, in a pivotal clinical trial has deepened some researchers’ concerns that it poses serious risks for patients who share the woman’s hard-to-diagnose, preexisting condition.
The patient’s history and autopsy “strongly suggests that lecanemab infusions were a catalyst leading to the events resulting in her death,” says Vanderbilt University pathologist Hannah Harmsen, co-author of a recently completed case report, which
Science
has obtained. The aut...
Source: Science of Aging Knowledge Environment - April 13, 2023 Category: Geriatrics Source Type: research
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
New Nasal Spray for Migraines Approved by FDA
MONDAY, March 13, 2023 – Migraine sufferers will soon have a new treatment option that works more quickly and may be safer for people at risk of heart attack or stroke.
The U.S. Food and Drug Administration has approved Pfizer Inc.’s zavegepant...
Source: Drugs.com - Daily MedNews - March 13, 2023 Category: General Medicine Source Type: news
New Nasal Spray for Migraines, Zavzpret, Approved by FDA
MONDAY, March 13, 2023– Migraine sufferers will soon have a new treatment option that works more quickly and may be safer for people at risk of heart attack or stroke.
The U.S. Food and Drug Administration has approved Pfizer Inc.’s...
Source: Drugs.com - Daily MedNews - March 13, 2023 Category: General Medicine Source Type: news
F.D.A. Approves New Nasal Spray for Migraines
Pfizer ’s treatment applies an approach that is different from some other products, which doctors say may make it safer for people at risk of heart attacks or stroke.
Source: NYT Health - March 10, 2023 Category: Consumer Health News Authors: Christina Jewett Tags: Migraine Headaches Drugs (Pharmaceuticals) Nerves and Nervous System Clinical Trials Food and Drug Administration Lancet Neurology, The (Journal) Pfizer Inc Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Here ’s an Alternative to Statins for Lowering Cholesterol
Statins have revolutionized heart disease by lowering cholesterol effectively—by up to 50% or more. But anywhere from 7% to 29% of people who take them may be more susceptible to its side effects, which include weakening of muscles and pain, and decide they can’t tolerate them. In a recent study published in JAMA Network Open, for example, researchers at Brigham and Women’s Hospital reported that more than 20% of patients seen at the hospital from 2000 to 2018 who were recommended to take statins refused to take them, and those who refused took three times as long to lower their LDL cholesterol to target ...
Source: TIME: Health - March 4, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate heart health Source Type: news
Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients
We thank P. Almagro and P. Martinez-Camblor for their interest in our work and for their salient comments. While we agree that there is no universally accepted definition of major adverse cardiovascular event (MACE), the US Food and Drug Administration (FDA) and the European Medicines Agency include nonfatal myocardial infarction and stroke as well as cardiovascular (CV) mortality in their MACE definition [1]. Importantly, this definition includes both haemorrhagic and ischaemic stroke [1–4]. In our study, we followed this classical "three-point" definition of MACE (including haemorrhagic strokes). While this definit...
Source: European Respiratory Journal - March 2, 2023 Category: Respiratory Medicine Authors: Yang, M.-J., Guo, S.-L., Sin, D. D. Tags: Correspondence Source Type: research
MRI for all: Cheap portable scanners aim to revolutionize medical imaging
.news-article__hero--featured .parallax__element{ object-position: 47% 50%; -o-object-position: 47% 50%; }
The patient, a man in his 70s with a shock of silver hair, lies in the neuro intensive care unit (neuro ICU) at Yale New Haven Hospital. Looking at him, you’d never know that a few days earlier a tumor was removed from his pituitary gland. The operation didn’t leave a mark because, as is standard, surgeons reached the tumor through his nose. He chats cheerfully with a pair of research associates who have come to check his progress with a new and potentially revolutionary device they are testing.
The cylind...
Source: Science of Aging Knowledge Environment - February 23, 2023 Category: Geriatrics Source Type: research
